Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis

Molecular Medicine

Volumn 20, Issue JULY-DECEMBER 2014, 2014, Pages 490-502

  Minato, Takahiro ^a   Tsutsumi, Mikihiro ^a   Tsuchishima, Mutsumi ^a   Hayashi, Nobuhiko ^a   Saito, Takashi ^a   Matsue, Yasuhiro ^a   Toshikuni, Nobuyuki ^a   Arisawa, Tomiyasu ^a   George, Joseph ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2E1; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; 4-HYDROXY-2-NONENAL; ALDEHYDE; TUMOR NECROSIS FACTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINGE DRINKING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INDUCTION; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATOCYTE BALLOONING; HISTOPATHOLOGY; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CELL DAMAGE; LIVER LEVEL; LIVER NECROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ALDEHYDES; ANIMALS; BINGE DRINKING; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; RATS; RATS, INBRED OLETF; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921061696     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00048     Document Type: Article

References (50)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc.55:434–8.
2. Sanyal AJ. (2002) AGA technical review in nonalcoholic fatty liver disease. Gastroenterology. 123:1705–25.
3. Younossi ZM. (1999) Nonalcoholic fatty liver disease. Curr. Gastroenterol. Rep.1:57–62.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. (1995) The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 22:1714–9.
5. Day CP, James OFW. (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology. 114:842–5.
6. Browning JD, Horton JD. (2004) Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest.114:147–52.
7. Burt AD, Mutton A, Day CP. (1998) Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol.15:246–58.
8. Matteoni CA, et al.(1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413–9.
9. Chitturi S, Farrell GC. (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver. Dis.21:27–41.
10. Paschos P, Paletas K. (2009) Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 13:9–19.
11. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology. 54:2185–97.
12. Jaeschke H, et al.(2002) Mechanisms of hepatotoxicity. Toxicol. Sci.65:166–76.
13. Raucy JL, et al.(1991) Induction of cytochrome P450IIE1 in the obese overfed rat. Mol. Pharmacol.39:275–80.
14. Leclercq IA, et al.(2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest.105:1067–75.
15. Fong DG, Nehra V, Lindor KD, Buchman AL. (2000) Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 32:3–10.
16. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. (2008) Free Radic. Biol. Med.44:723–38.
17. Takahashi T, Lasker JM, Rosman AS, Lieber CS. (1993) Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology. 17:236–45.
18. Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS. (1989) The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology. 10:437–46.
19. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. (2010) Role of alcohol metabolism in nonalcoholic steatohepatitis. PLoS One. 5:e9570.
20. Favreau LV, Malchoff DM, Mole JE, Schenkman JB. (1987) Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J. Biol. Chem.262:14319–26.
21. Gonzalez FJ. (2005) Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res.569:101–10.
22. Sato T, Asahi Y, Toide K, Nakayama N. (1995) Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Diabetologia. 38:1033–41.
23. Rector RS, et al.(2008) Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J. Physiol.586:4241–9.
24. Ota T, et al.(2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 132:282–93.
25. Moran TH, Bi S. (2006) Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects. Dev. Psychobiol.48:360–7.
26. Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press.
27. Theodorsen L, Stromme JH. (1976) Gammaglutamyl- 3-carboxy-14-nitroanilide: the substrate of choice for routine determinations of gammaglutamyl- transferase activity in serum? Clin. Chim. Acta.72:205–10.
28. Kayamori Y, Hatsuyama H, Tsujioka T, Nasu M, Katayama Y. (1999) Endpoint colorimetric method for assaying total cholesterol in serum with cholesterol dehydrogenase. Clin. Chem.45:2158–63.
29. Bucolo G, David H. (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem.19:476–82.
30. Fishman S, et al.(2007) Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 21:53–60.
31. Kleiner DE, et al.(2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–21.
32. Roth CL, et al.(2012) Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Tolllike receptor activation. Hepatology. 55:1103–11.
33. Amidi F, et al.(2007) M-30 and 4HNE are sequestered in different aggresomes in the same hepatocytes. Exp. Mol. Pathol.83:296–300.
34. Hu KQ, et al.(2004) Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J. Hepatol.40:147–54.
35. Farrell GC, Larter CZ. (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43(2 Suppl 1):S99–112.
36. Lieber CS, DeCarli LM. (1986) The feeding of ethanol in liquid diets. Alcohol Clin. Exp. Res.10:550–3.
37. Tamura S, Shimomura I. (2005) Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest.115:1139–42.
38. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35:898–904.
39. Tian C, et al.(2014) Long term intake of 0.1% ethanol decreases serum adiponectin by suppressing PPARã expression via p38 MAPK pathway. Food Chem. Toxicol.65:329–34.
40. Tang H, et al.(2012) Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin. Exp. Res.36:214–22.
41. Deng T, et al.(2011) A peroxisome proliferatoractivated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function. J. Biol. Chem.286:30723–31.
42. Moller DE. (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab.11:212–7.
43. Lin HZ, Yang SQ, Kujhada F, Ronnet G, Diehl AM. (2000) Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat. Med.6:998–1003.
44. Valenti L, et al.(2002) Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 122:274–80.
45. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:610–4.
46. Carmiel-Haggai M, Cederbaum AI, Nieto N. (2003) Binge ethanol exposure increases liver injury in obese rats. Gastroenterology. 125:1818–33.
47. Abdelmegeed MA, et al.(2013) CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic. Biol. Med.65:1238–45.
48. Dunn W, et al.(2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol.57:384–91.
49. Dunn W, Xu R, Schwimmer JB. (2008) Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology.47:1947–54.
50. Cotrim HP, et al.(2009) Effects of light-to- moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur. J. Gastroenterol. Hepatol.21:969–972.